Nevertheless, a preclinical study of RCC cell lines reported that decreased CDKN2A is associated with sensitivity to CDK4/6 inhibitors [44], with an effective response in KIRC with wild-type VHL and CDKN2A mutations due to palbociclib [45]. The gene discussed is VHL; the disease is renal cell carcinoma.